| Research Conducted under Existing $9.4 Million Cooperative Grant from NIAID PRINCETON, N.J., April 25, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further progress in the development of ThermoVax™, its proprietary vaccine thermostabilization technology. Progress has been based on additional characterization of the stability of prototype vaccines that have been kept at elevated temperat...continued SNGX |
Wednesday, April 25, 2012
Soligenix Announces Further Progress with ThermoVax(tm) for Long-Term Vaccine ThermoStability
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment